Drug intelligence / Profile preview

Respimune

Development stage: Unknown
Lead developer: Tablets India
Modality: Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
Administration: Oral

Overview

Respimune is a probiotic nutraceutical product developed by Tablets India Limited, designed to support respiratory immune health. It is formulated as an orodispersible powder contained in stick pack sachets, featuring a combination of two specific probiotic strains: *Lactobacillus acidophilus* NCFM and *Bifidobacterium lactis* Bi-07, at a total concentration of 10 billion CFU. The product aims to optimize respiratory health and enhance immune function by modulating the gut-lung axis, a bidirectional communication system between the intestinal microbiota and the lungs. It is marketed in India for oral administration and is intended to enhance the body's natural immune response against respiratory challenges.

Brand names: Respimune

Beyond the preview

Go deeper on Respimune.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Respimune.

Explore the full profile